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Recent work shows that S-adenosylmethionine (AdoMet) helps main-
tain normal liver function as chronic hepatic deficiency results in
spontaneous development of steatohepatitis and hepatocellular car-
cinoma. The mechanisms by which these nontraditional functions of
AdoMet occur are unknown. Here, we use knockout mice deficient in
hepatic AdoMet synthesis (MAT1A/) to study the proteome of the
liver during the development of steatohepatitis. One hundred and
seventeen protein spots, differentially expressed during the devel-
opment of steatohepatitis, were selected and identified by peptide
mass fingerprinting. Among them, 12 proteins were found to be
affected from birth, when MAT1A/ expression is switched on in WT
mouse liver, to the rise of histological lesions, which occurs at 8
months. Of the 12 proteins, 4 [prohibitin 1 (PHB1), cytochrome c
oxidase I and II, and ATPase -subunit] have known roles in mito-
chondrial function. We show that the alteration in expression of PHB1
correlates with a loss of mitochondrial function. Experiments in
isolated rat hepatocytes indicate that AdoMet regulates PHB1 con-
tent, thus suggesting ways by which steatohepatitis may be induced.
Importantly, we found the expression of these mitochondrial proteins
was abnormal in obob mice and obese patients who are at risk for
nonalcoholic steatohepatitis.
S -adenosylmethionine (AdoMet) is an essential metabolite in allcells. AdoMet serves as the methyl donor for many biological
methylation reactions, provides the propylamino group for the
synthesis of polyamines, and, in the liver, is an intermediary
metabolite in the synthesis of glutathione (1–4). Methionine ad-
enosyltransferase (MAT) catalyzes the only known AdoMet bio-
synthetic reaction from methionine and ATP (5, 6). In mammals,
there are three MAT isoforms (MAT I, MAT II, and MAT III)
encoded by two distinct genes (MAT1A and MAT2A; refs. 7–11).
MAT I and MAT III are a tetramer and a dimer, respectively, of
a catalytic 1-subunit encoded by the gene MAT1A (4, 6). A second
gene, MAT2A, encodes for a catalytic 2-subunit that forms MAT
II (4, 6). The three enzymes catalyze the same reaction, but their
cellular distribution, kinetics, and regulation are different. Al-
though MAT II is the only isoform expressed in extrahepatic tissues
(refs. 12 and 13; with the exception of the pancreas, which expresses
both MAT1A and MAT2A; ref. 14), both MAT III and I, and to a
lesser extent MAT II, are expressed in the liver (13). MAT II
expression also predominates in fetal liver and is progressively
replaced by MAT III and I during liver development (13). In adult
liver, increased expression of MAT2A is associated with rapid
growth or de-differentiation of the liver, as during liver regenera-
tion induced by partial hepatectomy (15, 16) and in hepatocarci-
nogenesis (17–19).
MAT1A silencing in extrahepatic tissues and during liver
neoplastic transformation correlates with methylation of the
gene promoter and its association with nonacetylated histones
(20). Seemingly, these epigenetic modifications may lead to a
condensed, transcriptionally inactive chromatin, as suggested by
the observation that MAT1A expression was up-regulated in
HepG2 hepatoma cells in the presence of inhibitors of DNA
methylation and histone deacetylation (20). It has been found
subsequently that liver samples from cirrhotic patients, who are
known to have an impaired methionine metabolism and are at
higher risk to develop hepatocellular carcinoma (HCC), show
increased methylation of MAT1A promoter, reduced abundance
of MAT1A mRNA, and decreased MAT activity (21).
The finding that MAT1A is expressed predominantly in adult
liver and that MAT III and I are replaced by MAT II during liver
neoplastic transformation suggests that these MAT isoforms have
distinct rather than overlapping biological roles. This question has
been addressed by the generation of MAT1A knockout (KO;
MAT1A/) mice (22). Homozygous KO mice were born at normal
Mendelian ratios, were fertile, and did not show gross anatomical
or behavioral abnormalities (22). In adult KO mice, liver MAT2A
expression was up-regulated to compensate for the absence of
MAT III and I (22). However, KO mice have hypermethioninemia
and reduced hepatic AdoMet content,20% of that in WT animals
(22). These results indicate that up-regulation of MAT2A expres-
sion in adult MAT1A/ mouse liver cannot compensate for the
absence of MAT III and I in maintaining normal AdoMet levels.
This finding is consistent with known differences in kinetics and
regulation between MAT isoforms. Whereas MAT II has a low Km
for methionine and is inhibited by physiological concentrations of
AdoMet (12, 23), MAT III and I have, respectively, a high and
intermediate Km for methionine, are activated by methionine and
ATP, and are not inhibited by physiological concentrations of
AdoMet (6–8, 11, 24, 25).
Cellular content of AdoMet seems to be related to the
differentiation status of the hepatocyte (26). In this regard,
quiescent and proliferating hepatocytes display different
AdoMet levels, being lower in growing (26). This correlation has
been observed in rat liver after partial hepatectomy (which
triggers the proliferation of the remaining parenchymal cells to
divide quickly and restore the original liver mass), where
AdoMet levels are dramatically reduced shortly after the inter-
vention coinciding with the onset of DNA synthesis and the
induction of the early-response genes (15, 16, 27). When this
decrease in AdoMet after partial hepatectomy was prevented by
the administration of AdoMet, hepatocyte DNA synthesis was
inhibited (19). Recent work shows that AdoMet helps turns off
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the hepatocyte responses to growth factors, and that without this
protection, the uncontrolled growth of cancer takes place (16).
Thus, it has been shown that KO mice deficient in AdoMet
synthesis (MAT1A/) spontaneously develop oxidative stress,
nonalcoholic steatohepatitis (NASH), and hepatocellular carci-
noma (22, 28), and in hepatoma cell lines, AdoMet inhibits
growth and induces apoptosis (18). The medical implication of
these observations has emerged by the finding that patients with
liver cirrhosis have impaired synthesis of AdoMet (29, 30). The
precise mechanisms by which these nontraditional functions of
AdoMet take place are unknown. Here, we use MAT1A/ mice
to carry out an extensive proteomic analysis of the liver during
the development of NASH. Our results show the existence of a
network of mitochondrial proteins regulated by AdoMet that
participate in the pathogenesis of the disease.
Materials and Methods
Materials. The following reagents and materials were used:
anti-cytochrome c oxidase (COX) subunits I and II antibodies
(Molecular Probes), anti-prohibitin 1 (PHB1) antibody (Calbio-
chem), anti-ATP synthase -subunit (Molecular Probes), elec-
trophoresis reagents (Bio-Rad), trypsin (Promega), urea and
collagenase (GIBCOBRL), and thiourea (Merck). All other
chemical reagents were from Sigma. Animals were from our
inbred colony and were treated humanely, according to our
institution’s guidelines. The human research review committee
of the Hospital Prı´ncipe de Asturias approved this study.
High-Throughput Proteomic Analysis. Liver samples were homoge-
nized in 20 volumes of lysis buffer containing 7 M urea, 2 M
thiourea, 4% (volvol) 3-[(3-cholamidopropyl)dimethylammonio]-
1-propanesulfonate, 1% (volvol) DTT, and 0.5% Bio-Lyte 310
ampholytes. The homogenates were centrifuged at 100,000 g for
45 min at 15°C. Protein concentration was determined in the
supernatants with the Bradford assay kit (Bio-Rad) by using
albumin diluted in lysis buffer as standard. First-dimensional iso-
electrofocusing was performed on a Protean IEF cell (Bio-Rad) by
using 17-cm ReadyStrips IPG strips (Bio-Rad) with different pH
ranges. Sample (300–700 g of protein) was loaded, and active
rehydration was performed for 12 h at 50 V and 20°C. Gels were
run for 60,000 Vh by using a progressively increasing protocol
implemented by the manufacturer. IPG strips were equilibrated in
50 mM TrisHCl, pH 7.56 M urea30% (vol/vol) glycerol2%
(vol/vol) SDS2% (vol/vol) DTT and then incubated in the same
buffer containing 2.5% iodoacetamide and bromophenol blue, in
the absence of DTT. IPG strips were directly loaded onto 12.5%
polyacrylamide gels (18 cm 20 cm 1 mm) and sealed with low
melting point agarose. Second-dimensional SDSPAGE gels were
run for 15 h. Gels were stained with Phastgel Blue R prepared in
65% H2O25% ethanol10% acetic acid. Alternatively, silver stain-
ing was performed by using the silver staining kit from Amersham
Pharmacia. Images were digitized with a Bio-Rad imaging densi-
tometer and analyzed by using PDQUEST software. Qualitative and
quantitative differences were detected and were only accepted
when at least a twofold change was confirmed in five independent
experiments. Gel spots corresponding to proteins differentially
expressed were picked up manually and processed on a MassPrep
station from Micromass (Manchester, U.K.). Gel specimens were
destained with 50 mM ammonium bicarbonate50% (vol/vol)
acetonitrile (Coomassie-stained gels) or 15 mM potassium ferri-
cyanide50 mM sodium thiosulphate (silver-stained gels). Then,
proteins were reduced with 10 mM DTT in 100 mM ammonium
bicarbonate and alkylated with 55 mM iodoacetamide in the same
buffer. In-gel protein digestion was performed with 6 ngl trypsin
in 50 mM ammonium bicarbonate for 5 h at 37°C. The resulting
peptides were extracted with 1% (vol/vol) formic acid2% (vol/vol)
acetonitrile. Finally, 2-l samples were mixed with 2 l of a
saturated solution of -cyano-4-hydroxy-transcinnamic acid in tri-
fluoroacetic acid 0.1%50% (vol/vol) acetonitrile and spotted into
a matrix-assisted laser desorption ionization (MALDI) target plate.
Tryptic digests were then analyzed on a MALDI–time-of-flight
(TOF) GL-REF mass spectrometer (Micromass). Data processing
was performed with MASSLYNX, and database searching (Swiss-
Prot, TrEMBL, Ensembl) to identify the proteins of interest from
their peptide fingerprint was performed with PROTEINLYNX
GLOBAL SERVER (Micromass). Data analysis and clustering was
performed with GARBAN. This system is implemented with bioin-
formatic tools that organize large amounts of genes and proteins
into biologically relevant clusters and classify them according to the
ontological criteria of the Gene Ontology Consortium (L. A.
Martı´nez-Cruz, A.R., and J.M.M., unpublished work).
Isolation and Culture of Rat Hepatocytes. Hepatocytes were isolated
from male Wistar rats (200–250 g) by collagenase perfusion, as
described (31). After isolation, hepatocytes were cultured ac-
cording to Garcı´a-Trevijano et al. (19) in the presence or absence
of 100 M methionine4 mM AdoMet20 mM cycloleucine
(CL) for the indicated periods of time. Cell viability was mea-
sured by trypan blue exclusion, and no significant differences
were observed at any time between controls and any of the
various treatments performed in this study.
Mitochondrial Isolation and Characterization. An enriched mitochon-
drial fraction was obtained from 100-mg liver specimens with the
Mitochondria Isolation kit from Sigma by two consecutive centrif-
ugation steps (600  g and 11,000  g, respectively). The electro-
chemical proton gradient () of the inner mitochondrial mem-
brane was tested by measuring uptake of the f luorescent
carbocyanine dye JC-1 (Sigma) into the mitochondria, following the
procedure indicated by the manufacturer. Briefly, samples of the
mitochondrial suspension containing 5–40 g of protein were
incubated for 7 min in the dark with 0.3 M JC-1 in the presence
of 10 mM sodium succinate. Fluorescence measurements were
performed with a Perkin–Elmer LS 50 B spectrofluorimeter.
RNA Isolation and Northern Hybridization Analysis. Total liver RNA
was isolated by the guanidinium thiocyanate method (19). RNA
concentration was determined spectrophotometrically before use,
and the integrity was checked by electrophoresis with subsequent
ethidium bromide staining. Electrophoresis and gel blotting were
carried out as described (22). The PHB1 cDNA was cloned by
reverse transcriptase-PCR from mouse liver. The Superscript pre-
amplification system (Life Technologies, Grand Island, NY), Taq
Long Plus enzyme (Stratagene), and the mouse prohibitin sense
5-atggctgccaaagtgtttgagtc-3 antisense 5-tcactggggaagctggagaagc-
3primers were used. Probes for the ATPase -subunit and COX
subunits I and II have been described (32, 33). Northern hybrid-
ization analyses were performed on total RNA by using standard
procedures, as described (22). All probes were labeled with
[32P]dCTP by using the Rediprime DNA Labeling System (Amer-
sham Pharmacia). To ensure equal loading of RNA samples,
membranes were also hybridized with a 32P-labeled 18S rRNA
cDNA probe. Autoradiography and densitometry were used to
quantitate relative RNA. Results of Northern blot analysis were
normalized to 18S rRNA.
DNA Isolation and Southern Blot Analysis. Total DNA was extracted
from the livers of 3-month-old WT and MAT1A/ mice, as
described (33). Total cellular DNA (20 g) was digested with
EcoRI. The digested DNA was resolved on 1% agarose gel,
transferred, and fixed onto nylon membranes. The membranes were
incubated with a COX II [32P]dCTP-labeled probe. Conditions for
hybridization and membrane washing were as described (33).
Western Blot Analysis. Protein extraction and Western blotting
were performed as described (34, 35). Equal amounts of protein
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(15 g) were resolved in SDS12.5% polyacrylamide gels. Pro-
teins were electrophoretically transferred to nitrocellulose mem-
branes. Membranes were probed with anti-MAT (35), anti-
PHB1, anti-ATPase , and anti-COX I and II. A horseradish
peroxidase-conjugated secondary antibody was used. Blots were
developed by enhanced chemiluminescence (Dupont).
Statistical Analysis. Data are given as the mean SD. For changes
in mRNA and protein levels, ratios of the respective mRNA or
protein to 18S or red Ponceau staining densitometric values were
compared between KO and WT mice by Student’s t test.
Significance was defined as P  0.05.
Results
Proteomic Fingerprint of the Pathogenesis of NASH in MAT1A/
Mouse. We have investigated the molecular mechanisms involved in
the development of NASH in the liver of MAT1A/ mouse by a
high-throughput proteomic approach. Protein expression patterns
were obtained by two-dimensional electrophoresis (2-DE) analysis
of liver extracts from 1-, 15-, 90-, and 240-day-old WT and
MAT1A/ mice. Five independent experiments were performed
by using liver extracts from different animals. Based on the results
of the image analysis with PDQUEST (Bio-Rad), an average of
1,500–2,000 spots were visualized, depending on the gel staining
procedure. WT and KO gel images (see Fig. 6, which is published
as supporting information on the PNAS web site, www.pnas.org)
were compared to determine the differences of protein expression,
and changes were only accepted when at least a twofold increase or
decrease was confirmed in all five experiments. Our analysis
revealed that 1 day after birth, 140 differences were already induced
in the liver of MAT1A/ mice, and that changes accumulate with
age (242, 259, and 297 differences by 15, 90, and 240 days,
respectively; see Fig. 7, which is published as supporting informa-
tion on the PNAS web site). The distribution between up-regulated
and down-regulated proteins is maintained up to 3 months; 53–70%
were up-regulated and 30–47% were down-regulated proteins. In
contrast, this pattern switches in 8-month-old KO liver, when
NASH has already developed, where 27% were up-regulated and
73% were down-regulated proteins (see Fig. 7). From all of the
original changes, because of technical reasons, only the most
abundant proteins represented in the databases were identified by
peptide mass fingerprinting, resulting in 117 proteins successfully
identified (see Table 1, which is published as supporting informa-
tion on the PNAS web site). Consequently, alterations other than
those reported in this study might also participate in the develop-
ment of NASH in MAT1A/ mice. We have found a linear
correlation between the Mr and pI calculated from the sequence of
the identified proteins and the experimental relative electro-
phoretic mobility (Rf) of the corresponding spot, calculated from
the 2-DE gels (see Fig. 8, which is published as supporting infor-
mation on the PNAS web site). This finding further validates the
identity of the analyzed spots. Some pI deviations of linearity were
observed, which is likely a consequence of posttranslational mod-
ifications. The specific protein expression profile of the MAT1A/
liver provides a proteomic fingerprint of NASH (see Fig. 6). Up-
and down-regulated proteins were classified by the biological
processes in which they are involved according to the gene ontology
criteria and were represented as shown in Fig. 1. Most proteins
differentially expressed in the KO liver clustered into three biolog-
ical processes (Fig. 1): cell communication (group 1), cell growth
andor maintenance (group 2), and developmental processes
(group 3). Some of the identified proteins in these clusters are
tubulin  6 chain, tubulin  5 chain, actin, and PHB1, which control
DNA synthesis and regulate cell proliferation. These proteins are
involved in embryogenesis, morphogenesis, and aging. Additionally,
proteins involved in response to stress, such as leukotriene A4
hydrolase (LKHA), heat shock cognate 71, and heat shock protein
75, are up-regulated. Changes in the expression pattern of proteins
Fig. 1. Proteins differentially expressed in the liver of MAT1A/ mouse
during the development of NASH. Liver extracts from 1-, 15-, 90-, and 240-
day-old WT and MAT1A/mice were analyzed by 2-DE. Proteins differentially
expressed were identified by matrix-assisted laser desorption ionization–
time-of-flight (MALDI-TOF) mass spectrometry and clustered by the biological
process in which they are involved according to gene ontology criteria: (i) cell
communication, (ii) cell growth andor maintenance, and (iii) developmental
processes. Up-regulated proteins are shown in red and down-regulated pro-
teins are shown in green. Proteins whose up- or down-regulation was con-
stantly detected in the liver of MAT1A/ mouse from 1 to 240 days are
indicated. APA1, ATP, LKHA, and PHB1 were clustered in different gene
ontology categories.
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involved in oxidative stress were also identified, for example,
glutathione peroxidase, antioxidant protein 1 and 2 (AOP2), or
Cu2Zn2 superoxide dismutase (SODC). Finally, according to
the broad metabolic activity of the liver, 80% of the proteins whose
expression changes in KO mouse correspond to metabolic enzymes.
Most of the alterations affect carbohydrate, lipid, and amino acid
metabolism. For example, fructose 1,6 biphosphatase (up-
regulated) and glycerol 3 phosphate dehydrogenase (down-
regulated) are key enzymes in gluconeogenesis and glycolysis,
respectively. Acyl CoA dehydrogenase long chain specific (ACDL)
and 3,5 2,4 dienoyl CoA isomerase (both down-regulated) are
involved in fatty acid -oxidation. Apolipoprotein A1 (APA1;
up-regulated) and farnesyl pyrophosphate synthetase (down-
regulated) participate in cholesterol transport and biosynthesis,
respectively, and malate dehydrogenase and isocitrate dehydroge-
nase (both down-regulated) catalyze two steps of the citrate cycle.
In addition, major differences affecting branched, aromatic, and
sulfur amino acid metabolism were identified (see Fig. 9, which is
published as supporting information on the PNAS web site). A
group of 12 proteins changed their expression pattern 1 day after
birth, and this alteration is maintained along the progression of
NASH in MAT1A/ liver (Fig. 1). These proteins, which can be
considered as early markers of NASH, were identified as APA1,
LKHA, selenium binding protein, AOP2, MAT, keratin type 1
cytoskeletal 18, guanidinoacetate methyltransferase, PHB1,
SODC, albumin, ACDL, and ATPase -subunit. Most of these
proteins are metabolic enzymes or participate in the antioxidant
response of the KO hepatocyte. Interestingly, PHB1 and ATPase
-subunit are mitochondrial proteins, and changes in their expres-
sion might compromise mitochondrial function.
AdoMet Regulates a Network of Mitochondrial Proteins and Mito-
chondrial Function. Alteration of mitochondrial function might be a
key factor in the progression of NASH in MAT1A/ mice.
Up-regulation (450  37%) of ATPase -subunit and down-
regulation (53  3%) of PHB1 were confirmed by Western blot
analysis with specific antibodies (Fig. 2). Additionally, the steady-
state levels of subunits I and II of COX were also diminished in KO
liver (55 7% and 53 5%, respectively; Fig. 2). These alterations
were not observed in other tissues (not shown). The expression of
genes encoding for these proteins was also investigated by Northern
blot analysis. The mRNA level of ATPase -subunit is increased
twofold in MAT1A/ liver (Fig. 2). In contrast, mRNA levels of
PHB1 and COX II, as well as 16S rRNA, were similar to those
found in the WT animals (Fig. 2). These observations indicate that
the down-regulation of PHB1 and COX subunits by AdoMet
involves posttranscriptional mechanisms. Whereas PHB1 is the
product of a nuclear gene, COX subunits are encoded by mito-
chondrial genes. Additionally, no changes on mitochondrial DNA
content were observed in MAT1A/ liver (Fig. 2). Changes on the
expression profile of PHB1, COX, and ATPase proteins suggest a
deficiency in mitochondrial respiration. The mitochondrial inner
membrane potential was measured in an enriched mitochondrial
fraction purified from liver extracts of WT and MAT1A/ mice. A
40% reduction of the electrochemical proton gradient was assessed
in the KO (Fig. 3), indicating a deficiency of the mitochondrial inner
membrane integrity.
Regulation of PHB1 by AdoMet. Next, we investigated whether
AdoMet regulates PHB1 levels in cultured rat hepatocytes. In
the presence of methionine or AdoMet in the culture media, no
effect on PHB1 protein levels was detected after a 24-h incu-
bation under standard conditions (Fig. 4). However, impairment
of AdoMet synthesis by restriction of methionine or addition of
CL, a well known inhibitor of MAT activity (36), to the culture
media resulted in the down-regulation of PHB1 (51  4% and
56  8%, respectively; Fig. 4). Restoration of hepatocyte intra-
cellular pool of AdoMet by exogenous addition of this compound
Fig. 2. (A) Hepatic steady-state PHB1, COX I and II, and ATP -protein levels
in MAT1A/ and WT liver. Liver extracts (15glane) from 1- and 240-day-old
mice were analyzed by Western blotting. Equal protein loading was assured
by red Ponceau staining of membranes (not shown). ATPasewas 484 51%
and 432 33%, up-regulated by 1 and 240 days, respectively. PHB1 was 62
4% and 54 6%, down-regulated by 1 and 240 days, respectively. COX I was
52  5% and 57  4%, down-regulated by 1 and 240 days, respectively. COX
II was 51 6% and 54 4%, down-regulated by 1 and 240 days, respectively.
(B) Expression of PHB1, COX II, ATP, and 16S rRNA in MAT1A/ and WT liver.
Liver RNA samples (30 glane) from 90-day-old mice were analyzed by
Northern blot hybridization with specific probes. Blots were hybridized with
a probe for 18S rRNA to check for equal loading. (C) mtDNA content in
MAT1A/ relative to WT liver. Total DNA was isolated from 3-month-old
mice, cleaved with EcoRI, and used for Southern analysis with a specific probe
for COX II. Equivalent amounts of DNA in each lane were ensured by ethidium-
bromide staining of the gel. Representative blots from three independent
experiments are shown.
Fig. 3. Electrochemical proton gradient of the inner mitochondrial mem-
brane. Mitochondrial functionality was studied by measuring  in an en-
riched mitochondrial fraction from 3-month-old WT and MAT1A/ liver.
Value of 100% was 175.51  6.69 fluorescence units per mg of protein. The
average of three independent experiments is shown. *, P  0.05 vs. WT by
Student’s t test.
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after a 12-h culture in the absence of methionine prevented the
fall of PHB1.
PHB1 and COX I and II Levels in ob/ob Mice and Obese Patients. To
evaluate whether the alterations observed in MAT1A/ mice
provide hitherto unknown mechanisms by which NASH may be
induced, the steady-state levels of PHB1 and COX were investi-
gated in liver samples from obob mice and obese patients; indi-
viduals with these conditions are prone to the development of
NASH. Western blot analysis revealed that PHB1 and COX I and
II are down-regulated in obob liver by 76 8%, 81 3%, and 70
5%, respectively. Down-regulation of PHB1 (53  4%) and COX
I (82  5%) was also confirmed in the liver of obese patients,
although the COX II level was similar to that found in control liver
(Fig. 5). Similar to MAT1A/ mice, the mRNA levels of PHB,
COX I, and COX II in obob mice and obese patients are
unchanged from normal controls (not shown).
Discussion
AdoMet generally has been considered as a central intermediary
metabolite involved in the synthesis of homocysteine and poly-
amines, as well as the main cellular methyl group donor (2).
However, recent evidence indicates that, in addition to its central
metabolic function, AdoMet functions in the liver as an intra-
cellular control switch that regulates essential hepatocyte func-
tions such as proliferation, differentiation, and death (26). To
better understand the mechanisms by which these nontraditional
functions of AdoMet take place, we studied the pathogenesis of
NASH in KO mice deficient in hepatic AdoMet synthesis
(MAT1A/) by using a high-throughput proteomic approach.
Analysis of the differential protein expression profile of
MAT1A/ and WT mice indicates that a chronic deficiency in
AdoMet synthesis has a pleiotropic effect in liver that alters
essential hepatic functions. The initial depletion of MAT1A
might result in changes in liver cell populations other than
hepatocytes, which may also contribute to the development of
NASH. We have identified 117 proteins that are differentially
expressed in the liver of MAT1A/ mice during the develop-
ment of NASH (see Table 1). The global analysis of the observed
differences indicates up-regulation of antioxidant proteins
(SODC, catalase, glutathione peroxidase) in the MAT1A/
liver that might reflect an adaptive mechanism to dissipate
oxidative stress generated by oxidant genes (22, 28). Major
metabolic alterations were also found at protein expression level
in the KO liver. Lipid, carbohydrate, and amino acid metabolism
is impaired in MAT1A/ mice from birth, although differences
accumulate during the development of NASH. These up- and
down-regulated proteins provide a specific proteomic profile
that might explain some of the metabolic alterations reminiscent
of those found in obesity and other conditions associated
with NASH, which lead to development of cirrhosis and HCC
(37–39).
The analysis of the 117 proteins differentially expressed on
MAT1A/ liver revealed that most of the changes detected 1 day
after birth are not maintained during the development of NASH.
These time-dependent differences may reflect the adaptation of
the hepatocyte to performing its normal biological function
under a chronic deficiency of AdoMet, leading to the accumu-
lation of alterations that condition the development of the
disease. However, 12 proteins change their expression pattern
after birth, when MAT1A is switched on in WT mice, and this
alteration is maintained to the onset of histological lesions.
Among these early changes are the up-regulation of SODC and
AOP2, which was deduced from our two-dimensional electro-
phoresis (2-DE) gels in accordance with earlier evidence (40), as
well as the down-regulation of ACDL and up-regulation of
APA1. These alterations agree with the implication of oxidative
stress and abnormal lipid metabolism in the pathogenesis of fatty
liver disease. Interestingly, four proteins involved in mitochon-
drial function were also identified, ATPase , COX I and II, and
PHB1. Transcriptional up-regulation of ATPase  has been
implicated in mitochondrial maturation and in cell neoplastic
transformation (41, 42), which is consistent with the proliferative
and de-differentiated state of MAT1A/ hepatocytes (22, 28).
Translational down-regulation of COX indicates a deficient
transference of electrons to oxygen, the last step of the mito-
chondrial electron transfer chain, and therefore provides a
molecular explanation for the oxidative stress found in
MAT1A/ liver (22, 28, 43). The fall in PHB1 steady-state levels
might explain the down-regulation of COX. PHB1 is the product
of a nuclear gene that is targeted to the inner mitochondrial
membrane (44). It has been proposed recently that PHB1 is a
chaperone-like protein that participates in the correct folding
and assembly of some of the components of the mitochondrial
respiratory chain (45, 46). According to this hypothesis, a
deficiency in PHB1 may impair the native and functional orga-
nization of respiratory proteins that are subsequently degraded
by mitochondrial proteases, compromising mitochondrial func-
tionality (45, 46). Therefore, the decrease of PHB1 might
induce a reduction of COX, with the concomitant loss of
mitochondrial function in MAT1A/ hepatocytes.
Previous evidence correlates down-regulation of PHB1 gene
expression with accelerating aging and age-related degenerative
diseases (46, 47). Our results indicate that AdoMet regulates
PHB1 levels, likely through a posttranslational mechanism, as
Fig. 4. Regulation of PHB1 levels by AdoMet in cultured rat hepatocytes.
PHB1 levels were measured in rat hepatocytes cultured for 12 or 24 h in the
presence or absence of 100 M methionine4 mM AdoMet or 20 mM cyclo-
leucine. (Right) AdoMet (4 mM) was added after 12-h culture in a methionine-
deficient media. Liver extracts (15 g per lane) were analyzed by Western
blotting by using specific antibodies. PHB1 was down-regulated by 51  4%
and 56 8% by the restriction of methionine or the addition of cycloleucine,
respectively. Equal protein loading was assured by red Ponceau staining of
membranes (not shown). A representative blot from three independent ex-
periments is shown.
Fig. 5. (A) Hepatic steady-state protein levels of PHB1 and COX I and II in WT
and obob mice. A representative blot from three independent experiments
is shown. PHB1 and COX I and II are down-regulated in obob liver by 76 8%,
81 3%, and 70 5%, respectively. (B) Hepatic steady-state protein levels of
PHB1 and COX I in control and obese patients. Liver extracts (15 g per lane)
were analyzed by Western blotting by using specific antibodies. PHB1 and
COX I are down-regulated by 53  4% and 82  5% in the liver of obese
patients. Equal protein loading was assured by red Ponceau staining of
membranes (not shown).
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deduced from the observation that mRNA content of PHB1
remains normal in liver under a chronic deficiency of AdoMet.
The correlation between a deficiency of AdoMet synthesis and
down-regulation of PHB1 found in MAT1A/ mice was con-
firmed by the in vitro experiments on isolated rat hepatocytes.
Reduction of AdoMet synthesis by using a culture media without
methionine or in the presence of CL, an inhibitor of MAT
activity (36), results in the down-regulation of PHB1. Replen-
ishment of hepatocyte AdoMet content prevented the fall of
PHB1. The mechanism by which AdoMet regulates PHB1 levels
requires further investigation. However, phosphorylation of
PHB1 has been reported in human fibroblasts (48) and in
hormone-treated ovarian cells (49), and the ability to posttrans-
lationally phosphorylate PHB1 is lost during the process of
cellular aging (48).
PHB1 steady-state levels are also decreased in the liver of
obob mice and in obese patients who are predisposed to develop
NASH. NASH is a chronic disorder with an increasing preva-
lence in the population and is fast becoming one of the most
significant and common disorders of clinical hepatology (37).
The pathogenesis of NASH is poorly understood, but present
evidence supports mitochondrial alterations correlating with
oxidative stress as one of the most important factors (37, 50).
Down-regulation of PHB1 and COX induced by a chronic
deficiency of hepatic AdoMet may provide new molecular
mechanisms involved in the pathogenesis of NASH. The results
of our experiments with MAT1A/mice indicate that PHB1 and
COX fell long before any histological manifestation of the
disease was detected. Furthermore, our data also suggest one of
the key mechanisms of AdoMet’s hepatoprotective action may
be to restore the expression of PHB1. Whether AdoMet might
be of benefit in the treatment of NASH should be investigated
further.
In summary, our results provide a mechanism by which a
deficiency of AdoMet impairs mitochondrial function and gen-
erates oxidative stress in liver. The fall of PHB1 leading to a
mitochondrial failure, together with abnormal lipid, carbohy-
drate, and amino acid metabolism might explain, at least in part,
the pathogenesis of NASH.
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